{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:27:34Z","timestamp":1789637254041,"version":"4.0.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UMSC C.A.R.E Fund Research Grant","award":["UMG006C-2024"],"award-info":[{"award-number":["UMG006C-2024"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>Most international guidelines recommend a two-step approach using the Fibrosis-4 index (FIB-4) and vibration-controlled transient elastography (VCTE) to identify advanced fibrosis, a key predictor of all-cause and liver-related mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, VCTE is not available in most primary care settings in Malaysia, and there is scarce data on the cost-effectiveness of different approaches. This study evaluated the cost-effectiveness of three referral pathways for identifying advanced fibrosis among type 2 diabetes mellitus(T2DM) patients with MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a decision-analytical model from the healthcare provider\u2019s perspective, using 1,000 simulated patients to compare: (i) Current Practice (direct referral based on elevated alanine transaminase), (ii) Clinical Practice Guidelines (CPG) Pathway using FIB-4 single-cutoff 1.3, and (iii) FIB-4 dual-cutoffs (1.3,3.25) followed by a gamma-glutamyl transferase (GGT) test for indeterminate cases (Sequential FIB-4\/GGT Pathway). Current practice served as the reference comparator. The primary outcomes were the average cost-effectiveness ratio (ACER) and the incremental cost-effectiveness ratio (ICER). Model parameters were mainly derived from local studies. Direct medical costs were reported in 2024 Malaysian Ringgit (MYR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sequential FIB-4\/GGT pathway had the lowest ACER at MYR930 per advanced fibrosis case identified, compared to MYR1,299 for current practice and MYR1,581 for the CPG pathway. Sequential FIB-4\/GGT pathway was potentially more effective and less costly, demonstrating dominance over current practice with a cost savings of MYR2,911\/additional advanced fibrosis case identified. CPG pathway was more effective and more costly than current practice, with an ICER of MYR3,785.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sequential FIB-4\/GGT pathway was cost-effective for identifying advanced fibrosis in T2DM patients with MASLD. This pragmatic approach could reduce tertiary care referrals, lower healthcare resource use and costs compared to current practice. CPG pathway was more effective than current practice, but incurred higher costs and required increased availability of VCTE within clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0350263","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T17:36:51Z","timestamp":1779989811000},"page":"e0350263","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of various referral pathways to identify advanced fibrosis among type 2 diabetes mellitus patients with metabolic dysfunction-associated steatotic liver disease in primary care setting in Malaysia"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0532-5051","authenticated-orcid":true,"given":"Wei Yoon","family":"Poh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirah","family":"Azzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsul Mohd","family":"Zain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosmawati","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Sui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xe Hui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maznah","family":"Dahlui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatiha Hana","family":"Shabaruddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"10","key":"pone.0350263.ref001","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"ZM Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"pone.0350263.ref002","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"VW-S Wong","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"pone.0350263.ref003","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1111\/jgh.16666","article-title":"Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"39","author":"W Wongtrakul","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"17","key":"pone.0350263.ref004","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"AJ Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0350263.ref005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"ZM Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"pone.0350263.ref006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"pone.0350263.ref007","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Y Sumida","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"5","key":"pone.0350263.ref008","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: A comprehensive cost-utility analysis","volume":"159","author":"M Noureddin","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"pone.0350263.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147237","article-title":"Cost-effectiveness analysis: Risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score","volume":"11","author":"EB Tapper","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"pone.0350263.ref010","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"S McPherson","year":"2010","journal-title":"Gut"},{"issue":"6","key":"pone.0350263.ref011","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"PJ Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"10","key":"pone.0350263.ref012","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"AG Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"pone.0350263.ref013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.15605\/jafes.038.01.08","article-title":"The prevalence of advanced liver fibrosis among patients with type 2 diabetes mellitus: A single-centre experience in Penang, Malaysia","volume":"38","author":"XH Lee","year":"2023","journal-title":"J ASEAN Fed Endocr Soc"},{"issue":"6","key":"pone.0350263.ref014","doi-asserted-by":"crossref","first-page":"916","DOI":"10.14309\/ajg.0000000000000153","article-title":"Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease","volume":"114","author":"S Petta","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"pone.0350263.ref015","article-title":"Improving stratification of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease patients with type-2 diabetes mellitus in low-resource settings","author":"WY Poh","year":"2026","journal-title":"Int J Diabetes Dev Ctries"},{"key":"pone.0350263.ref016","year":"2020"},{"issue":"6","key":"pone.0350263.ref017","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"RK Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"pone.0350263.ref018","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.02.059","article-title":"Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications","volume":"21","author":"J Boursier","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"pone.0350263.ref019","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"S McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"pone.0350263.ref020","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/jgh3.12414","article-title":"Use of simple scoring systems for a public health approach in the management of non-alcoholic fatty liver disease patients","volume":"4","author":"SM Zain","year":"2020","journal-title":"JGH Open"},{"issue":"2","key":"pone.0350263.ref021","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/10543406.2013.860157","article-title":"Cost-effectiveness analysis: A proposal of new reporting standards in statistical analysis","volume":"24","author":"H Bang","year":"2014","journal-title":"J Biopharm Stat"},{"issue":"1","key":"pone.0350263.ref022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated reporting guidance for health economic evaluations","volume":"25","author":"D Husereau","year":"2022","journal-title":"Value Heal"},{"issue":"1","key":"pone.0350263.ref023","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1186\/s12889-025-22762-9","article-title":"The prevalence of metabolic syndrome and the associated factors in a multiethnic upper-middle-income country in Asia: Findings from a nationwide community-based study in 2023","volume":"25","author":"KS Wan","year":"2025","journal-title":"BMC Public Health"},{"issue":"8","key":"pone.0350263.ref024","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/jgh.14577","article-title":"Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography","volume":"34","author":"L-L Lai","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"pone.0350263.ref025","article-title":"Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis","volume":"17","author":"WK Chan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"pone.0350263.ref026","article-title":"Clinical characteristics of patients with chronic hepatitis C infection at initial presentation to tertiary care in an Asian Middle-Income Country","volume":"20","author":"A Azzeri","year":"2017","journal-title":"Value in Health"},{"key":"pone.0350263.ref027","author":"Department of Statistics Malaysia"},{"issue":"9","key":"pone.0350263.ref028","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"S Verma","year":"2013","journal-title":"Liver Int"},{"issue":"3","key":"pone.0350263.ref029","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes","volume":"48","author":"AL Fracanzani","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"pone.0350263.ref030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2036.2008.03896.x","article-title":"Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels","volume":"29","author":"VW-S Wong","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"pone.0350263.ref031","doi-asserted-by":"crossref","first-page":"101280","DOI":"10.1016\/j.aohep.2023.101280","article-title":"Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT","volume":"29","author":"J Lee","year":"2024","journal-title":"Ann Hepatol"},{"key":"pone.0350263.ref032","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12072-024-10661-x","article-title":"MAFLD in adults: Non-invasive tests for diagnosis and monitoring of MAFLD","volume":"18","author":"W-K Chan","year":"2024","journal-title":"Hepatol Int"},{"issue":"2","key":"pone.0350263.ref033","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","article-title":"The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease","volume":"19","author":"M Eslam","year":"2025","journal-title":"Hepatol Int"},{"issue":"11","key":"pone.0350263.ref034","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","article-title":"Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease","volume":"68","author":"VW-S Wong","year":"2019","journal-title":"Gut"},{"key":"pone.0350263.ref035","year":"2024"},{"key":"pone.0350263.ref036","author":"Ministry of Human Resources","year":"2024"},{"issue":"1","key":"pone.0350263.ref037","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"A Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"pone.0350263.ref038","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/liv.14198","article-title":"Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis","volume":"39","author":"C Crossan","year":"2019","journal-title":"Liver Int"},{"issue":"5","key":"pone.0350263.ref039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251741","article-title":"Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting","volume":"16","author":"SE Congly","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"pone.0350263.ref040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.04.017","article-title":"Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system","volume":"18","author":"E Vilar-Gomez","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"pone.0350263.ref041","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"M Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"pone.0350263.ref042","doi-asserted-by":"crossref","first-page":"686","DOI":"10.47102\/annals-acadmedsg.2022284","article-title":"Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis","volume":"51","author":"BP Choo","year":"2022","journal-title":"Ann Acad Med Singap"},{"issue":"4","key":"pone.0350263.ref043","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"S Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"pone.0350263.ref044","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cgh.2025.07.011","article-title":"Longitudinal changes in fibrosis markers: Monitoring stiffness\/fibrosis progression and prognostic outcomes in MASLD","volume":"24","author":"X Zhou","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"pone.0350263.ref045","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"H Hagstr\u00f6m","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"pone.0350263.ref046","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/liv.15255","article-title":"Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study","volume":"42","author":"W Balkhed","year":"2022","journal-title":"Liver Int"},{"key":"pone.0350263.ref047","first-page":"445","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"MF Drummond","year":"2015","edition":"4"},{"issue":"4","key":"pone.0350263.ref048","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000075","article-title":"The Steatosis-associated fibrosis estimator (SAFE) score: validation in the general US population","volume":"7","author":"LA van Kleef","year":"2023","journal-title":"Hepatol Commun"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T17:37:00Z","timestamp":1779989820000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350263"}},"subtitle":[],"editor":[{"given":"Seth Agyei","family":"Domfeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0350263","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}